Skip to Content

Vyvanse (lisdexamfetamine) Disease Interactions

There are 6 disease interactions with Vyvanse (lisdexamfetamine):

Major

Amphetamines (Includes Vyvanse) ↔ Cardiovascular

Severe Potential Hazard, Moderate plausibility

Applies to: Cerebral Vascular Disorder, Cardiovascular Disease, Heart Disease, History - Cerebrovascular Disease, History - Myocardial Infarction, Hyperthyroidism

The use of amphetamines and amphetamine-like drugs is contraindicated in patients with advanced arteriosclerosis, symptomatic or unstable cardio- or cerebrovascular disease, moderate to severe hypertension, or hyperthyroidism. Like other sympathomimetic amines, amphetamines may cause cardiovascular adverse effects such as palpitation, tachycardia, cardiac arrhythmias, and elevation of blood pressure. Rarely, cardiomyopathy manifested as ventricular hypertrophy and/or congestive heart failure has been reported during chronic amphetamine use. In addition, sudden death has been reported in association with amphetamine therapy at usual dosages in children with structural cardiac abnormalities. In general, amphetamines should not be used in patients with structural cardiac abnormalities. If not otherwise contraindicated, therapy with amphetamines should be administered cautiously in patients with a current or past history of cardiovascular or cerebrovascular disease.

References

  1. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  2. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  3. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  4. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  5. Ayres PR "Amphetamine cardiomyopathy [letter]." Ann Intern Med 98 (1983): 110
  6. Gibbs HR "Diet pills and sudden death." N Engl J Med 318 (1988): 1127
  7. Kokkinos J, Levine SR "Possible association of ischemic stroke with phentermine." Stroke 24 (1993): 310-3
  8. Bashour TT "Acute myocardial infarction resulting from amphetamine abuse: a spasm- thrombus interplay." Am Heart J 128 (1994): 1237-9
  9. Ragland AS, Ismail Y, Arsura EL "Myocardial infarction after amphetamine use." Am Heart J 125 (1993): 247-9
  10. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  11. Smith HJ, Roche AH, Jausch MF, Herdson PB "Cardiomyopathy associated with amphetamine administration." Am Heart J 91 (1976): 792-7
  12. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  13. Douglas A, Douglas JG, Robertson CE, Munro JF "Plasma phentermine levels, weight loss and side-effects." Int J Obes 7 (1983): 591-5
  14. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  15. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
View all 15 references
Major

Amphetamines (Includes Vyvanse) ↔ Glaucoma

Severe Potential Hazard, Moderate plausibility

Applies to: Glaucoma/Intraocular Hypertension

The use of amphetamines and amphetamine-like drugs is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles. Like other sympathomimetic amines, amphetamines can induce transient mydriasis. In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma. If possible, these agents should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.

References

  1. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  2. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  3. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  4. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
  5. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  6. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  7. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  8. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
View all 8 references
Major

Cns Stimulants (Includes Vyvanse) ↔ Agitation

Severe Potential Hazard, Moderate plausibility

Applies to: Neurosis, Psychosis, Anxiety/Stress

The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated. CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children. Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.

References

  1. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  2. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  4. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  5. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  6. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  7. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
  8. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
  9. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  10. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  11. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
View all 11 references
Major

Cns Stimulants (Includes Vyvanse) ↔ Substance Abuse

Severe Potential Hazard, Moderate plausibility

Applies to: Alcoholism, Drug Abuse/Dependence

Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse. Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use. Frank psychotic episodes may also occur in association with chronic intoxication. Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse. The use of amphetamines is considered by manufacturers to be contraindicated in such patients.

References

  1. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  4. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  5. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
  6. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  7. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  8. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
  9. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  10. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  11. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
View all 11 references
Major

Cns Stimulants (Includes Vyvanse) ↔ Tics

Severe Potential Hazard, Moderate plausibility

Applies to: Tic Disorder

Central nervous system (CNS) stimulants have been reported to exacerbate Tourette's syndrome and other motor and phonic tics. Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette's syndrome. The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.

References

  1. "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
  2. "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
  4. "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
  5. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  6. "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
  7. "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
  8. "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
  9. "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
  10. "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
  11. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
View all 11 references
Moderate

Cns Stimulants (Includes Vyvanse) ↔ Seizure Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures

Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures. These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures. Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures. If seizures appear, therapy should be discontinued.

References

  1. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):

Vyvanse (lisdexamfetamine) drug Interactions

There are 527 drug interactions with Vyvanse (lisdexamfetamine)

Vyvanse (lisdexamfetamine) alcohol/food Interactions

There is 1 alcohol/food interaction with Vyvanse (lisdexamfetamine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide